Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06528990
Recruiting
Telehealth Intervention for Ostomy Self-Management
Phase 2 · United States · 1 site
Registry update: 5 Mar 2026
NCT07379281
Recruiting
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
Not applicable · China · 1 site
Registry update: 30 Jan 2026
NCT06904573
Recruiting
Probiotics in Advanced Urothelial Carcinoma
Phase 2 · China · 3 sites
Registry update: 1 Apr 2025
NCT07379255
Recruiting
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
Not applicable · China · 1 site
Registry update: 30 Jan 2026
NCT07379268
Recruiting
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
Not applicable · China · 1 site
Registry update: 30 Jan 2026
NCT07187063
Recruiting
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Not applicable · United States · 1 site
Registry update: 3 Nov 2026
NCT06263153
Recruiting
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Phase 2 · United States · 3 sites
Registry update: 1 Oct 2026
NCT06729346
Recruiting
Is the Normal Looking Bladder Mucosa on WL Cystoscopy During TURBT Really Normal and Can NBI Detect Hidden Tumor
Not applicable · Pakistan · 1 site
Registry update: 29 Jan 2025
NCT06851663
Recruiting
Trop2-targeted immunoPET Imaging of Solid Tumors
Phase 2/3 · China · 1 site
Registry update: 29 May 2026
NCT06245603
Recruiting
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Not applicable · Italy · 9 sites
Registry update: 4 Aug 2026
NCT06525571
Recruiting
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Phase 3 · United States · 2 sites
Registry update: 3 Nov 2026
NCT06724159
Recruiting
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Not applicable · Spain · 84 sites
Registry update: 17 Feb 2026
NCT06738797
Recruiting
Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients With Advanced or Metastatic Urothelial Carcinoma
Not applicable · France · 5 sites
Registry update: 28 Jan 2026
NCT06645808
Recruiting
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Early phase 1 · Netherlands · 1 site
Registry update: 29 Dec 2025
Conflicting statuses (not updated in the registry for 10 months)
NCT06580002
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Phase 2 · United States · 1 site
Registry update: 14 Jul 2026
NCT07324798
Recruiting
Adaptive Radiotherapy for Genitourinary Cancers
Not applicable · China · 1 site
Registry update: 7 Jan 2026
NCT06679920
Recruiting
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
Not applicable · Netherlands · 1 site
Registry update: 6 Dec 2024
NCT06735287
Recruiting
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
Not applicable · China · 1 site
Registry update: 18 Mar 2025
NCT06806059
Recruiting
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
Not applicable · Germany · 1 site
Registry update: 27 Apr 2026
2024-516077-72-02
Recruiting
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08
Phase 2 · France · 1 site
Registry update: 28 Nov 2024

Ordered by registry start date. Freshness and sponsorship never change the order.